The Clinical Trial Patient Experience: Balancing Science, Technology, and Humanity

The clinical trial community knows the patient retention problem well. What is less settled is how to solve it, especially as the pressure to capture richer patient-reported data intensifies. Human-centered design, applied across the full trial ecosystem, offers a practical path forward.

As featured in International Clinical Trials, pages 39-41

By Bruce Hellman, Chief Patient Officer & Co-Founder, and Ben James, Chief Design Officer & Co-Founder, uMotif

The Real Opportunity in Clinical Trial Design

Patient engagement and data quality are often treated as competing priorities, as though designing a better experience for participants will inherently compromise scientific rigor. That framing is worth challenging. The tools and processes used to capture patient-reported data, including electronic clinical outcome assessment (eCOA) and electronic patient-reported outcome (ePRO) solutions, can be designed to serve both objectives simultaneously. In most cases where they fail to do so, the shortfall is a design problem, not an unavoidable tradeoff between good science and good experience.

The stakes are rising. There’s growing emphasis by sponsors and regulatory agencies on patient-reported experiences and outcomes, which are now considered in the approval process for most new therapeutics. Cancer drug clinical trials, for example, increasingly measure quality of life (QoL) alongside survival, and patient-reported data is essential to this metric. The completeness and consistency of patient-reported data has become a direct scientific requirement, which means the participant’s willingness to keep submitting it is one as well.

Patients are not the only people whose experience shapes clinical trial data quality. Site staff are under mounting pressure as an expanding set of clinical requirements, administrative loads, and technology platforms has made the coordination role significantly more complex. When the systems site teams depend on add friction rather than reduce it, the consequences reach the patient. Overburdened coordinators have less capacity to communicate proactively, respond to compliance issues early, or maintain the kind of relationship with participants that keeps them engaged. Designing for the human experience in clinical trials means designing for site personnel as much as for participants.

Four Dimensions of Effective eCOA Design

Innovation in clinical data capture technology does not occur in a single dimension. The principles of human-centered design evaluate solutions across four dimensions: what is scientifically viable, what is technically feasible, what is ethically and regulatorily responsible, and, critically, what is genuinely desirable to the humans who must use it. Good clinical practice (GCP) compliance, data integrity, electronic signatures, audit trails, and system validation are well-understood obligations, and the industry has made substantial progress in meeting them. What is less consistently addressed is desirability: whether a platform actually reduces burden, fits into a participant’s daily life, and creates an experience that supports continued engagement.

Clinical trial participants today live in a world defined by consumer technology. Their expectations are calibrated by apps that complete tasks in a few taps, surface relevant information at the right moment, and adapt to individual preferences over time. When a clinical trial application compares poorly to these everyday experiences, participants notice and engagement and compliance suffer.

Consider a hypothetical but typical ePRO diary experience. A participant with a chronic pain condition is asked to complete a daily symptom assessment, a weekly quality-of-life questionnaire, and a medication log — each accessed through separate modules with different navigation patterns on a provisioned device they use only for the study. The burden is real, even if each individual task seems modest. A human-centered approach would look to consolidate those touchpoints into a single intuitive flow, surfacing only what is needed at the moment it is needed, on the device the participant already carries.

Artificial intelligence (AI) adds a new dimension to this equation. AI holds genuine promise for accelerating build processes, surfacing compliance risk early, and personalizing participant communications. Where its use is viable within the constraints of GCP, validated systems, and ethical data governance, it deserves consideration. For example, AI-driven compliance monitoring can flag participants at risk of dropout based on engagement patterns, giving site coordinators an early signal to intervene before a participant disengages entirely. This is AI working within validated parameters, supporting human relationships rather than replacing them. The goal is to deploy technology in ways that serve the participant experience without compromising scientific standards.

Human-Centered Design: Principles in Practice

Human-centered design (HCD) begins by reframing a fundamental clinical trial question. Instead of asking “how do we get patients to comply with a protocol?” it asks, “how do we make participation fit naturally into people’s lives?” That shift has practical consequences at every level of platform design.

Usability in eCOA and ePRO platforms is shaped by many factors, and design choices at every level accumulate into the overall participant experience.

Clear visual hierarchy reduces cognitive load. In an event-driven diary, for example, colors and visual cues can be used to make the linkage between an event and subsequent associated symptoms immediately apparent, ensuring that participants capture data in the right sequence and context. It also can help to assure that the data collected accurately reflects reality rather than a participant’s best reconstruction of it after the fact.

Intuitive navigation shortens time-to-completion. For example, a well-designed eCOA home screen presents all required tasks clearly, with the most time-sensitive items at the top, so participants never have to search for what they need to do next. Equally important is visible progress feedback. When a task is clearly marked as completed, participants experience a small but meaningful sense of accomplishment that reinforces the behavior and supports continued compliance over the life of the study.

Flexible notification timing respects individual routines. Rather than applying a fixed reminder schedule to all participants, platforms can offer options, within protocol guidelines, that allow participants to select windows that fit their lives. For example, a patient who works the night-shift may prefer a very different prompt cadence than someone on a standard daytime work schedule. Removing that mismatch between a participant’s routine and their study obligations can be an effective way to boost compliance.

Accessibility features extend inclusion across age groups and ability levels. Adjustable text size, high-contrast display modes, and compatibility with screen readers are baseline requirements for any platform deployed across a broad patient population. Older participants, those managing conditions that affect vision or fine motor control, and those using assistive technology by habit should encounter no additional friction in completing study requirements.

Behavioral science provides a rigorous foundation for these choices. Principles of motivation, reinforcement, habit formation, and framing translate directly to the clinical context. When data entry becomes a habit rather than a task, completeness improves and missing data queries fall. When participants receive meaningful communication about how their contributions are advancing research, their sense of purpose and commitment strengthens. Applying the same principles in eCOA design —for example, showing participants a simple summary of their own trends, or acknowledging milestones in their participation—can activate a motivational mechanism without adding burden.

To enable effective capture of patient-reported data, clinical trial technology, including eCOA and ePRO, must also be familiar. The industry’s growing adoption of bring-your-own device (BYOD) models reflects this understanding. Asking participants to report on their own phones, rather than unfamiliar provisioned devices, removes a meaningful barrier to engagement and mirrors the digital habits people already have.

Strengthening the Patient-Site Relationship through Design

Human-centered design applies not only to the participant experience, but to the full ecosystem of people involved in a trial. Site staff are under increasing pressure: a growing universe of clinical requirements, administrative responsibilities, and technology tools has made the coordination role significantly more demanding. A 2023 survey of over 500 clinical research professionals found that nearly 60% of sites reported higher study volumes alongside a growing technology burden, which was rated by coordinators as more demanding than contracting and budgeting combined.i When the systems they depend on add complexity rather than reduce it, the consequences ripple outward to the patients they support.

The industry is responding. There is growing emphasis on tools such as eConsent that can meaningfully strengthen the patient-site relationship without adding new layers of complexity for either party. The goal is technology that enhances communication, reinforces trust, and keeps site staff genuinely connected to the participants in their care without making an already demanding job harder.

The pandemic-driven acceleration of decentralized trials demonstrated what is possible in remote data collection. The pendulum is now moderating. Rather than fully remote or fully in-person, the industry is converging on hybrid models that use digital tools to extend and strengthen the human connection between patients and site teams. Feeling known, supported, and valued by real people remains one of the most powerful drivers of retention in clinical research. Technology works best when it makes that relationship more informed, more timely and more effective.

A Shared Imperative

Data quality and participant engagement need not be at odds. When participation is designed around the realities of participants’ lives, completion rates improve, missing data declines, and the scientific record strengthens.

As regulatory expectations around patient-reported outcomes continue to grow, and as competition for participants’ attention increases, the quality of the trial experience will become even more important.

When patients and site teams are treated as the starting point rather than an afterthought—in trial design and in the technology built to support it—the result is research that is more resilient, more inclusive, and more capable of delivering on its promise.

Placing patients and site teams at the center of both trial design and the technology that supports it is how the industry produces studies that retain participants, generate complete and high-quality data, and meet the highest standards of scientific integrity.